|
Brussels, |
|
Read the Table of Content
|
eDossier EUPHARMA
PHARMACEUTICAL
|
Summary
This eDossier offers a comprehensive analysis of the European Union's regulatory framework governing Pharmaceutical Products, alongside recent initiatives and legislative developments. It delves into the EU's efforts to ensure the safety, efficacy, and quality of medicinal products for human use while promoting innovation and competitiveness within the pharmaceutical industry.
The dossier covers key regulations, including the EU's Pharmaceutical Strategy for Europe, the revision of general pharmaceutical legislation, and specific directives related to the authorization, monitoring, and pharmacovigilance of medicinal products. It examines initiatives aimed at enhancing access to affordable medicines, addressing unmet medical needs, and fostering the development of advanced therapies and personalized medicine.
Additionally, the eDossier explores the impact of recent events, such as the COVID-19 pandemic, on EU pharmaceutical policies. It highlights measures taken to strengthen supply chains, improve crisis preparedness, and accelerate the development and approval of vaccines and treatments.
The document also addresses the EU's approach to digitalization in healthcare, including the use of health data and the integration of artificial intelligence in drug development and regulatory processes.
By providing in-depth information on current legislative work, regulatory procedures, and policy debates, this eDossier equips stakeholders with the knowledge needed to navigate the complex EU pharmaceutical landscape.
It enables professionals, policymakers, and industry to engage effectively with European institutions and contribute to shaping the future of pharmaceutical regulation in the EU.
The dossier covers key regulations, including the EU's Pharmaceutical Strategy for Europe, the revision of general pharmaceutical legislation, and specific directives related to the authorization, monitoring, and pharmacovigilance of medicinal products. It examines initiatives aimed at enhancing access to affordable medicines, addressing unmet medical needs, and fostering the development of advanced therapies and personalized medicine.
Additionally, the eDossier explores the impact of recent events, such as the COVID-19 pandemic, on EU pharmaceutical policies. It highlights measures taken to strengthen supply chains, improve crisis preparedness, and accelerate the development and approval of vaccines and treatments.
The document also addresses the EU's approach to digitalization in healthcare, including the use of health data and the integration of artificial intelligence in drug development and regulatory processes.
By providing in-depth information on current legislative work, regulatory procedures, and policy debates, this eDossier equips stakeholders with the knowledge needed to navigate the complex EU pharmaceutical landscape.
It enables professionals, policymakers, and industry to engage effectively with European institutions and contribute to shaping the future of pharmaceutical regulation in the EU.
* PaaS, Cloud-Based
This publication is offered as a Product-as-a-Service (PaaS), combining products with accompanying services for a one-time fee. Accessible in the cloud at any time and from anywhere for a period of one year, you no longer need to download the document to all your devices. Simply access it online using computers, tablets, or smartphones, on any operating system.
We offer this PaaS product to provide it with multiple life cycles. Ownership is not transferred; instead, our company remains responsible for delivering an improved product by providing constant updates and changes throughout your entire subscription period.
This publication is offered as a Product-as-a-Service (PaaS), combining products with accompanying services for a one-time fee. Accessible in the cloud at any time and from anywhere for a period of one year, you no longer need to download the document to all your devices. Simply access it online using computers, tablets, or smartphones, on any operating system.
We offer this PaaS product to provide it with multiple life cycles. Ownership is not transferred; instead, our company remains responsible for delivering an improved product by providing constant updates and changes throughout your entire subscription period.
